Inhibition of reverse-mode sodium-calcium exchanger activity and apoptosis by levosimendan in human cardiomyocyte progenitor cell-derived cardiomyocytes after anoxia and reoxygenation

PLoS One. 2014 Feb 3;9(2):e85909. doi: 10.1371/journal.pone.0085909. eCollection 2014.

Abstract

Levosimendan, a known calcium sensitizer with positive inotropic and vasodilating properties, might also be cardioprotective during ischemia-reperfusion (I/R) insult. Its effects on calcium homeostasis and apoptosis in I/R injury remain unclear. Na(+)/Ca(2+) exchanger (NCX) is a critical mediator of calcium homeostasis in cardiomyocytes, with reverse-mode NCX activity responsible for intracellular calcium overload and apoptosis of cardiomyocytes during I/R. We probed effects and underlying mechanisms of levosimendan on apoptosis and NCX activity in cultured human cardiomyocyte progenitor cells (CPC)-derived cardiomyocytes undergoing anoxia-reoxygenation (A/R), simulating I/R in vivo. Administration of levosimendan decreased apoptosis of CPC-derived cardiomyocytes induced by A/R. The increase in reverse-mode NCX activity after A/R was curtailed by levosimendan, and NCX1 was translocated away from the cell membrane. Concomitantly, endoplasmic reticulum (ER) stress response induced by A/R was attenuated in CPC-derived cardiomycytes treated with NCX-targeted siRNA or levosimendan, with no synergistic effect between treatments. Results indicated levosimendan inhibited reverse-mode NCX activity to protect CPC-derived cardiomyocytes from A/R-induced ER stress and cell death.

MeSH terms

  • Adolescent
  • Apoptosis / drug effects*
  • Blotting, Western
  • Cardiotonic Agents / pharmacology
  • Cell Hypoxia
  • Cell Membrane / drug effects
  • Cell Membrane / metabolism
  • Cells, Cultured
  • Child
  • Endoplasmic Reticulum Stress / drug effects
  • Female
  • Flow Cytometry
  • HEK293 Cells
  • Humans
  • Hydrazones / pharmacology*
  • Male
  • Microscopy, Confocal
  • Myocytes, Cardiac / cytology
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Oxygen / pharmacology
  • Pyridazines / pharmacology*
  • RNA Interference
  • Simendan
  • Sodium-Calcium Exchanger / antagonists & inhibitors*
  • Sodium-Calcium Exchanger / genetics
  • Sodium-Calcium Exchanger / metabolism
  • Stem Cells / drug effects*
  • Stem Cells / metabolism

Substances

  • Cardiotonic Agents
  • Hydrazones
  • Pyridazines
  • Sodium-Calcium Exchanger
  • sodium-calcium exchanger 1
  • Simendan
  • Oxygen

Grants and funding

The authors have no support or funding to report.